MoezAlIslam Faris1, Haitham Jahrami2, Dana Abdelrahim3, Nicola Bragazzi4, Ahmed BaHammam5. 1. Department of Clinical Nutrition and Dietetics, College of Health Sciences/Research Institute for Medical and Health Sciences (RIMHS), University of Sharjah, Sharjah, United Arab Emirates. Electronic address: mfari@sharjah.ac.ae. 2. Rehabilitation Services, Periphery Hospitals, Ministry of Health, Manama, Bahrain; College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain. 3. Department of Nutrition and Food Technology, Faculty of Agriculture, The University of Jordan, Amman, Jordan. 4. Department of Mathematics and Statistics, Laboratory of Industrial and Applied Mathematics (LIAM), York University, Toronto, Canada. 5. Department of Medicine, College of Medicine, University Sleep Disorders Center, King Saud University, Riyadh, Saudi Arabia; The Strategic Technologies Program of the National Plan for Sciences and Technology and Innovation in the Kingdom of Saudi Arabia, Riyadh, Saudi Arabia.
Abstract
INTRODUCTION: Growing evidence is suggestive that intermittent fasting likely to improve liver function; however, still the evidences are controversial to draw a definitive conclusion. Therefore, we conducted a systematic review and meta-analysis to estimate the effect size for changes in liver function tests (LFT) in healthy people practicing Ramadan diurnal intermittent fasting (RDIF), and to examine the impact of different covariates using subgroup analysis and meta-regression. METHODS: Scientific databases were searched from date of inception in 1950 to the end of July 2020. The liver function tests searched and analyzed were aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), bilirubin (BLU), L-lactate dehydrogenase (LDH) and prothrombin time (PT). RESULTS: Twenty studies (601 adult participants in total, aged 18-57 years) conducted in 10 countries between 1987 and 2020 were identified. RDIF-induced effect sizes for the LFT expressed as standardized mean difference (SMD) [95% confidence interval] were: AST (no. of studies K = 16, number of subjects N = 502, SMD = -0.257 [-0.381, -0.133], I2 = 42%); ALT (K = 16, N = 502, SMD = -0.105 [-0.282, 0.07], I2 = 71%); GGT (K = 2, N = 46, SMD = -0.533 [-0.842, -0.224], I2 = 0%); ALP (K = 10, N = 312, SMD = -0.318 [-0.432, -0.204], I2 = 0.0%); BLU (K = 10, N = 325, SMD = -0.264 [-0.520, -0.007], I2 = 70.1%); LDH (K = 5, N = 145, SMD = -0.041 [-0.380, 0.298], I2 = 72%); PT (K = 2, N = 74, SMD = -0.027 [-0.732, 0.678], I2 = 87%). CONCLUSION: RDIF induces significant but small (AST, ALP, BLU) to medium (GGT) positive changes on LFT, and may confer a transient, short-term protection against fatty liver disease in healthy subjects.
INTRODUCTION: Growing evidence is suggestive that intermittent fasting likely to improve liver function; however, still the evidences are controversial to draw a definitive conclusion. Therefore, we conducted a systematic review and meta-analysis to estimate the effect size for changes in liver function tests (LFT) in healthy people practicing Ramadan diurnal intermittent fasting (RDIF), and to examine the impact of different covariates using subgroup analysis and meta-regression. METHODS: Scientific databases were searched from date of inception in 1950 to the end of July 2020. The liver function tests searched and analyzed were aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), bilirubin (BLU), L-lactate dehydrogenase (LDH) and prothrombin time (PT). RESULTS: Twenty studies (601 adult participants in total, aged 18-57 years) conducted in 10 countries between 1987 and 2020 were identified. RDIF-induced effect sizes for the LFT expressed as standardized mean difference (SMD) [95% confidence interval] were: AST (no. of studies K = 16, number of subjects N = 502, SMD = -0.257 [-0.381, -0.133], I2 = 42%); ALT (K = 16, N = 502, SMD = -0.105 [-0.282, 0.07], I2 = 71%); GGT (K = 2, N = 46, SMD = -0.533 [-0.842, -0.224], I2 = 0%); ALP (K = 10, N = 312, SMD = -0.318 [-0.432, -0.204], I2 = 0.0%); BLU (K = 10, N = 325, SMD = -0.264 [-0.520, -0.007], I2 = 70.1%); LDH (K = 5, N = 145, SMD = -0.041 [-0.380, 0.298], I2 = 72%); PT (K = 2, N = 74, SMD = -0.027 [-0.732, 0.678], I2 = 87%). CONCLUSION: RDIF induces significant but small (AST, ALP, BLU) to medium (GGT) positive changes on LFT, and may confer a transient, short-term protection against fatty liver disease in healthy subjects.
Authors: Mohamed I Madkour; Lara J Bou Malhab; Wael M Abdel-Rahman; Dana N Abdelrahim; Maha Saber-Ayad; MoezAlIslam E Faris Journal: Front Nutr Date: 2022-03-17
Authors: Mohamed Negm; Ahmed Bahaa; Ahmed Farrag; Rania M Lithy; Hedy A Badary; Mahmoud Essam; Shimaa Kamel; Mohamed Sakr; Waleed Abd El Aaty; Mostafa Shamkh; Ahmed Basiony; Ibrahim Dawoud; Hany Shehab Journal: BMC Gastroenterol Date: 2022-04-24 Impact factor: 2.847
Authors: Rachida Roky; Nadia Aadil; Al Mehdi Krami; Brahim Benaji; Ikram Errabih; Dana N Abdelrahim; MoezAlIslam Ezzat Faris Journal: Front Nutr Date: 2022-07-01